Salud financiera de hoja de balance de Cyclo Therapeutics

Salud financiera controles de criterios 4/6

Cyclo Therapeutics tiene un patrimonio de los accionistas total de $4.8M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $13.2M y $8.5M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$9.25m
Patrimonio	US$4.76m
Total pasivo	US$8.49m
Activos totales	US$13.25m

Actualizaciones recientes sobre salud financiera

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Jan 20

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Nov 16

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Sep 28

Cyclo therapeutics to join Russell 2000 Index

Jun 14

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Jun 12

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Cyclo Therapeutics' lead candidate shows durable benefit in Niemann-Pick Disease

Jan 05

How Much Is Cyclo Therapeutics, Inc. (NASDAQ:CYTH) CEO Getting Paid?

Dec 12

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($12.3M) de CYTH superan a sus pasivos a corto plazo ($8.5M).

Pasivo a largo plazo: Los activos a corto plazo de CYTH ($12.3M) superan a sus pasivos a largo plazo ($22.5K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: CYTH está libre de deudas.

Reducción de la deuda: CYTH no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: CYTH tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: CYTH tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 27.3% cada año

Salud financiera de hoja de balance de Cyclo Therapeutics

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Cyclo Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Recent updates

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

CEO & Director exercised options to buy US$293k worth of stock.

Consensus revenue estimates decrease by 29%, EPS upgraded

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board

New major risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc., Annual General Meeting, Jul 31, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director

CEO & Director recently bought US$213k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Provides Clinical Program Update

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Commences Phase 2B Study of Trappsol Cyclo for the Treatment of Early Alzheimer’S Disease

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$10.00

Consensus revenue estimates increase by 16%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclo Therapeutics to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics, Inc. Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Independent Vice Chairman recently bought US$53k worth of stock

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 3Q 2020)

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$1.60 loss in 2Q 2020)

Consensus forecasts updated

Cyclo Therapeutics, Inc. Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics Provides Update on Trappsol® Cyclo

Cyclo therapeutics to join Russell 2000 Index

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics Provides Business Update

First quarter 2021 earnings released: US$0.76 loss per share (vs US$2.18 loss in 1Q 2020)

Cyclo Therapeutics, Inc. Announces Design of Pivotal Phase 3 Study Evaluating Trappsol Cyclo in Niemann-Pick Type C1

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Independent Chairman recently bought US$81k worth of stock

Full year 2020 earnings released: US$5.59 loss per share (vs US$6.96 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Cyclo Therapeutics, Inc. Appoints Russ Belden as Acting Chief Commercial Officer

Cyclo Therapeutics, Inc. Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on Agreement of Paediatric Investigation Plan for Trappsol® Cyclo™

Cyclo Therapeutics, Inc. Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer

Cyclo Therapeutics, Inc. Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021

New 90-day high: US$13.15

Independent Chairman recently bought US$64k worth of stock

Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo™ in Patients with Niemann-Pick Disease Type C

Cyclo Therapeutics' lead candidate shows durable benefit in Niemann-Pick Disease

Independent Vice Chairman recently bought US$140k worth of stock

New 90-day low: US$3.98

How Much Is Cyclo Therapeutics, Inc. (NASDAQ:CYTH) CEO Getting Paid?

Cyclo Therapeutics, Inc. has completed a Composite Units Offering in the amount of $12.5 million.

Cyclo Therapeutics, Inc. announced that it has received $2.831114 million in funding from Novit, L.P.